Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GERN Stock Forecast 2026-2027
$1.39
Current Price
$891.71M
Market Cap
Buy 4
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to GERN Price Targets
+259.7%
To High Target of $5.00
+187.8%
To Median Target of $4.00
+115.8%
To Low Target of $3.00
GERN Price Momentum
-12.0%
1 Week Change
-21.0%
1 Month Change
+17.8%
1 Year Change
+5.3%
Year-to-Date Change
-30.8%
From 52W High of $2.01
+33.7%
From 52W Low of $1.04
📊 TOP ANALYST CALLS
Did GERN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Geron is one of their latest high-conviction picks.
Latest GERN Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, GERN has a bullish consensus with a median price target of $4.00 (ranging from $3.00 to $5.00). The overall analyst rating is Buy (7.7/10). Currently trading at $1.39, the median forecast implies a 187.8% upside. This outlook is supported by 4 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Gil Blum at Needham, projecting a 259.7% upside. Conversely, the most conservative target is provided by Corinne Jenkins at Goldman Sachs, suggesting a 115.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GERN Analyst Ratings
4
Buy
1
Hold
1
Sell
GERN Price Target Range
Low
$3.00
Average
$4.00
High
$5.00
Current: $1.39
Latest GERN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GERN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 5, 2025 | Needham | Gil Blum | Buy | Maintains | $4.00 |
| Jul 10, 2025 | Goldman Sachs | Corinne Jenkins | Sell | Reinstates | $1.00 |
| May 8, 2025 | Scotiabank | Greg Harrison | Sector Perform | Downgrade | $1.50 |
| Mar 12, 2025 | HC Wainwright & Co. | Emily Bodnar | Neutral | Reiterates | $N/A |
| Mar 12, 2025 | Needham | Gil Blum | Buy | Reiterates | $5.00 |
| Feb 27, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $4.00 |
| Feb 27, 2025 | Barclays | Peter Lawson | Overweight | Maintains | $4.00 |
| Feb 27, 2025 | Stifel | Stephen Willey | Buy | Maintains | $4.00 |
| Feb 27, 2025 | Needham | Gil Blum | Buy | Maintains | $5.00 |
| Feb 26, 2025 | HC Wainwright & Co. | Emily Bodnar | Neutral | Downgrade | $N/A |
| Feb 18, 2025 | B. Riley Securities | Kalpit Patel | Buy | Maintains | $3.50 |
| Jan 13, 2025 | Needham | Gil Blum | Buy | Maintains | $7.00 |
| Dec 13, 2024 | Needham | Gil Blum | Buy | Reiterates | $6.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $9.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $8.00 |
| Nov 5, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Initiates | $8.00 |
| Oct 16, 2024 | Scotiabank | Greg Harrison | Sector Outperform | Initiates | $6.00 |
| Sep 9, 2024 | Leerink Partners | Faisal Khurshid | Outperform | Initiates | $7.00 |
| Aug 9, 2024 | Needham | Gil Blum | Buy | Reiterates | $6.00 |
| Jul 26, 2024 | Needham | Gil Blum | Buy | Reiterates | $6.00 |
Geron Corporation (GERN) Competitors
The following stocks are similar to Geron based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Geron Corporation (GERN) Financial Data
Geron Corporation has a market capitalization of $891.71M with a P/E ratio of -10.7x. The company generates $196.12M in trailing twelve-month revenue with a -34.3% profit margin.
Revenue growth is +30.9% quarter-over-quarter, while maintaining an operating margin of -0.5% and return on equity of -27.1%.
Valuation Metrics
Market Cap
$891.71M
Enterprise Value
$612.80M
P/E Ratio
-10.7x
PEG Ratio
-0.4x
Price/Sales
4.5x
Growth & Margins
Revenue Growth (YoY)
+30.9%
Gross Margin
+97.3%
Operating Margin
-0.5%
Net Margin
-34.3%
EPS Growth
+1.0%
Financial Health
Cash/Price Ratio
+33.8%
Current Ratio
6.8x
Debt/Equity
0.5x
ROE
-27.1%
ROA
-4.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Geron Corporation (GERN) Business Model
About Geron Corporation
What They Do
Biopharmaceutical company focused on blood cancers.
Business Model
Geron Corporation generates revenue primarily through its product RYTELO, a telomerase inhibitor approved for treating lower-risk myelodysplastic syndromes. The company is expanding its commercial efforts and clinical programs, which has led to substantial growth in net product revenue.
Additional Information
Founded in 1990 and based in Foster City, California, Geron is dedicated to developing innovative therapies for patients with serious blood disorders. The company is advancing its Phase 3 IMpactMF trial for potential label expansion in myelofibrosis and is engaged in various studies to support its research and development initiatives.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
258
CEO
Mr. Harout Semerjian
Country
United States
IPO Year
1996
Website
www.geron.comGeron Corporation (GERN) Latest News & Analysis
Latest News
Quick Summary
Geron Corporation (GERN) held its Q1 2026 earnings call, discussing financial results and future strategies. Further details can be found in the transcript.
Why It Matters
Geron Corporation's Q1 2026 earnings call provides insights into its financial performance, growth prospects, and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
3 days ago
Quick Summary
In Q1 2026, RYTELO® generated $51.8 million in net revenue, up 8% from Q4 2025. The company expects 2026 revenue of $220-$240 million and expenses of $230-$240 million. Cash reserves total $341 million.
Why It Matters
RYTELO's Q1 revenue growth and strong cash position signal financial health, while leadership changes may enhance strategy execution, influencing future performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Geron (GERN) reported a quarterly loss of $0.01 per share, better than the expected loss of $0.03, and an improvement from a loss of $0.03 per share a year earlier.
Why It Matters
Geron's smaller-than-expected loss signals improved financial performance, potentially boosting investor confidence and affecting stock price positively.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Geron Corporation (Nasdaq: GERN) will present at the Bank of America Securities 2026 Healthcare Conference on May 12 at 4:35 p.m.
Why It Matters
Geron Corporation's upcoming presentation at a major healthcare conference could signal potential growth opportunities, attract investor interest, and impact stock performance based on investor sentiment and insights shared.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Geron Corporation (Nasdaq: GERN) will release its Q1 2026 financial results on May 6, 2026, and host a conference call at 8:00 a.m. ET. Press release available on their website.
Why It Matters
Geron's upcoming financial results and business update may impact stock performance and investor sentiment, especially in the biopharmaceutical sector focused on blood cancer therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Geron Corporation granted stock options for 855,000 shares to nine new employees as an inducement for employment acceptance, effective April 17, 2026.
Why It Matters
Geron's grant of stock options to new employees signals growth potential and recruitment efforts, which may enhance investor confidence in the company’s future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About GERN Stock
What is Geron Corporation's (GERN) stock forecast for 2026?
Based on our analysis of 18 Wall Street analysts, Geron Corporation (GERN) has a median price target of $4.00. The highest price target is $5.00 and the lowest is $3.00.
Is GERN stock a good investment in 2026?
According to current analyst ratings, GERN has 4 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $1.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GERN stock?
Wall Street analysts predict GERN stock could reach $4.00 in the next 12 months. This represents a 187.8% increase from the current price of $1.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Geron Corporation's business model?
Geron Corporation generates revenue primarily through its product RYTELO, a telomerase inhibitor approved for treating lower-risk myelodysplastic syndromes. The company is expanding its commercial efforts and clinical programs, which has led to substantial growth in net product revenue.
What is the highest forecasted price for GERN Geron Corporation?
The highest price target for GERN is $5.00 from Gil Blum at Needham, which represents a 259.7% increase from the current price of $1.39.
What is the lowest forecasted price for GERN Geron Corporation?
The lowest price target for GERN is $3.00 from Corinne Jenkins at Goldman Sachs, which represents a 115.8% increase from the current price of $1.39.
What is the overall GERN consensus from analysts for Geron Corporation?
The overall analyst consensus for GERN is bullish. Out of 18 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $4.00.
How accurate are GERN stock price projections?
Stock price projections, including those for Geron Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 7:37 AM UTC